NCT03625830Unknown不适用
A Randomized, Multicenter Study on the Efficacy and Safety of Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please) Compared to POBA in the Treatment of Small Vessel Disease (SVD) Patient
B. Braun Medical International Trading Company Ltd.1 个研究点 分布在 1 个国家目标入组 270 人开始时间: 2017年12月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 270
- 试验地点
- 1
- 主要终点
- Late lumen loss in segment section at M9
研究概览
简要总结
The purpose is to evaluate the safety and effectiveness of paclitaxel-releasing coronary balloon (Catheter SeQuent® Please) versus rapid exchange PTCA balloon catheter (SeQuent® Neo) in the treatment of stenoses of coronary small vessels. 270 subjects will be enrolled for the trials.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Criteria related to subjects
- •Patients with stable angina pectoris, or unstable angina pectoris, or old myocardial infarction, or documented silent ischemia;
- •At the age of 18-80;
- •Women of childbearing potential may not be pregnant nor have the desire to becoming pregnant during the study. Hence, patients will be advised to use an adequate birth control method up to (including) the end of follow-up;
- •Patients must agree to undergo the 9-month angiographic follow-up and the clinical follow-up at 30 days, 6 months, 9 months and 12 months after operation;
- •Patients who are psychologically and linguistically able to understand the purpose of the study, and show sufficient compliance with the study protocol;
- •Patients who have expressed acknowledgment of the risks and benefits described in the informed consent document by providing informed consent;
- •Criteria related to lesions
- •The target lesion is primary, in situ coronary artery lesion located in 1 or 2 different coronary arteries, with no more than 1 target lesion in each coronary artery;
- •The reference vessel diameter is within the range of 2.0 mm - 2.75 mm; (visually measured)
- •Interventional treatment should be conducted on lesion(s) of non-target vessel(s) in advance (which must be concurrent treatment), and management of random and target lesions should be performed after successful treatment of non-target lesion(s);
- •The pre-operative diameter stenosis must be either ≥ 70% or ≥ 50% with ischemia; (visually measured)
- •Each target lesion should be treated with only one SeQuent® Please or SeQuent® Neo.
排除标准
- •Criteria related to subjects
- •Patients with recent myocardial infarction (within one week), or patients with myocardial infarction over one week but whose troponin level has not recovered to normal;
- •Patients with severe congestive heart failure or NYHA class IV heart failure;
- •Patients with severe valvular heart disease;
- •Women who are pregnant or lactating;
- •Patients with remaining life expectancy of no more than 1 year or with factors causing difficulty in clinical follow-up;
- •Patients who had cerebral stroke within 6 months before operation;
- •Patients who are currently involved in any other clinical trial;
- •Patients with presence or history of severe hepatic failure and therefore are not eligible for angiography;
- •Patients with presence or history of severe renal failure (GFR < 30 ml/min) and therefore are not eligible for angiography;
- •Patients who have received heart transplant;
- •Patients with cardiogenic shock;
- •Patients with left ventricular ejection fraction less than 30%;
- •Patients suffering from coronary artery spasm without significant stenosis;
- •Patients considered as ineligible by the investigator for other reasons;
- •Criteria related to lesions
- •Evidence of extensive thrombosis in target vessel before intervention;
- •Percutaneous coronary intervention of venous graft;
- •Chronic total occlusion (TIMI 0 flow before operation);
- •Left main disease and/or triple vessel disease needed to be treated, bifurcation lesion with branch vessel diameter ≥ 2.5 mm, and bypass graft lesion;
- •There is non-target lesion(s) in the proximal large vessel and target lesion(s) in the distal small vessel of the same vessel (eligible if there is non-target lesion(s) in proximal large vessel and a target lesion in the bifurcated small vessel);
- •The target vessel is distorted or has calcified lesion(s);
- •Lesion within 5 mm away from the coronary artery ostium;
- •Lesion that cannot be treated with PTCA or other interventional techniques;
- •After pre-dilation of target lesion, the residual stenosis is ≥ 30% or TIMI flow is < 3, and/or type C or above dissection appears;
- •Exclusion criteria related to concomitant medication
- •Patients prone to bleeding and contraindicated for anticoagulant or antiplatelet drugs;
- •Patients who are intolerant to aspirin and/or clopidogrel or have a history of neutrophilopenia or thrombocytopenia, or patients with severe hepatic insufficiency and contraindicated for clopidogrel.
- •Patients who are known to be intolerant or allergic to heparin, contrast agent, paclitaxel, iopromide, rapamycin, polylactic acid - glycolic acid polymer, stainless steel;
- •Patients with a history of leukopenia (leukocyte count < 3 × 109/L for more than 3 days), neutrophilopenia (ANC < 1,000 neutrophils/mm3 for more than 3 days), or thrombocytopenia (< 100,000 platelets/mm3);
- •Patients with a history of peptic ulcer or gastrointestinal bleeding in the past 6 months
结局指标
主要结局
Late lumen loss in segment section at M9
时间窗: 9 months
To measure the diameter loss in the in-segment late lumen loss (LLL) at 9 months after operation by using angiography
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent RestenosisCoronary RestenosisNCT02944890ZhuHai Cardionovum Medical Device Co., Ltd.242
尚未招募
不适用
Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters Swide®Coronary Artery DiseaseNCT06024525Shanghai Shenqi Medical Technology Co., Ltd236
Unknown
4 期
Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary LesionsCoronary Artery DiseaseNCT01278186B.Braun Surgical SA190
已完成
不适用
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo LesionsCoronary Artery DiseaseNCT05096442Genoss Co., Ltd.204
已完成
不适用
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please in Korean Patients With Coronary In-stent RestenosisCoronary Artery DiseaseNCT04405063Genoss Co., Ltd.82